Precision medicine trial targets genetic flaw in Tough-to-Treat bile duct cancer
NCT ID NCT07282262
Summary
This study is testing whether a targeted drug called ivosidenib, when combined with other cancer therapies, can help control advanced bile duct cancer in patients who have a specific genetic change called an IDH1 mutation and whose cancer has worsened after standard chemotherapy. The trial will enroll 300 participants across multiple hospitals to see how well the treatment works and how safe it is. Researchers will measure whether tumors shrink, how long the cancer stays under control, and how long patients live.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Peking Union Medical College Hospital Outpatient Department
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.